Vascular calcification
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The importance of fetuin-A in vascular calcification in children with chronic kidney disease.
|
30070080 |
2019 |
Vascular calcification
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Fetuin-A, which plays a protective role against the atherosclerosis and progression of vascular calcification, is decreased in patients on hemodialysis (HD).
|
30128921 |
2018 |
Vascular calcification
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Fetuin-A is a negative acute phase reactant which inhibits calcium-phosphorus precipitation and vascular calcification.
|
29288724 |
2018 |
Vascular calcification
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The aim of our study was to determine VC in HD patients, the relationship between VC and 25-OH-vitamin D, fetuin-A, and OPN levels, and independent predictors of VC.
|
29134617 |
2018 |
Vascular calcification
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
During outpatient visits, plasma samples of all patients were obtained and analyzed for sST2 (hemodynamics and inflammation), galectin-3 (fibrosis and remodeling), GDF-15 (remodeling and inflammation), suPAR (inflammation), and fetuin-A (vascular calcification) by use of ELISA after informed consent.
|
29652038 |
2018 |
Vascular calcification
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We examined the relationships in stable PD patients between phase angle (PhA) and the spectrum of uremic vasculopathy including vascular calcification and arterial stiffness and between PhA and changes in serum fetuin-A levels.
|
28096437 |
2018 |
Vascular calcification
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The main purpose of this study was evaluating the correlation between fetuin-A and PTX3 with some biochemical parameters effective upon vascular calcification in HD patients.
|
29664315 |
2017 |
Vascular calcification
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Fetuin-A is a member of protease inhibitors that act as an inhibitor of vascular calcification.
|
24990392 |
2015 |
Vascular calcification
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We studied the determinants of fetuin-A, a potent circulating calcification inhibitor encoded by the AHSG gene, and tested its association with vascular calcifications and long-term survival and cardiovascular events (CVEs) in RTRs.
|
21527649 |
2011 |
Vascular calcification
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The fetuin-A polymorphism (Thr256Ser) is associated with reduced fetuin levels and accelerated vascular calcification in dialysis patients.
|
19110009 |
2009 |
Vascular calcification
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Among these mediators, studies on fetuin-A deserve further attention as clinical studies consistently show that fetuin-A deficiency is associated with vascular calcification, all-cause and cardiovascular mortality in CKD patients.
|
19004191 |
2008 |
Vascular calcification
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Vascular calcification and fetuin-A deficiency in chronic kidney disease.
|
17482094 |
2007 |
Vascular calcification
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Fetuin-A, also known as alpha(2)-Heremans-Schmid glycoprotein (AHSG), is a circulating plasma protein with inhibitory effects on VC that has been associated with inflammation and CV mortality in HD patients.
|
17851232 |
2007 |
Vascular calcification
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Fetuin-A, a circulating calcium-regulatory glycoprotein that inhibits vascular calcification, is associated with inflammation and outcome in dialysis patients.
|
15882283 |
2005 |